Compare Annaly Capital Management, Inc. (NLY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs GeneDx Holdings Corp — how do they compare? Annaly Capital Management, Inc. trades at $18.2 (market cap $13.77B), while GeneDx Holdings Corp trades at $67.59 (market cap $2.02B). The key difference: Annaly Capital Management, Inc. is far larger — about 6.8× GeneDx Holdings Corp's market cap, and Annaly Capital Management, Inc. pays a 16.42% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and GeneDx Holdings Corp for 19 Days on average.
| NLY | WGS | |
|---|---|---|
Market Cap | $13.77B | $2.02B |
Volume | 21,283,879 | 734,640 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $167.51 |
52-Week Low | $17.93 | $34.51 |
Typical Hold Time | 92 Days | 19 Days |
Enterprise Value | $135.80B | $2.05B |
Dividend Yield | 16.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $18.07, up 0.78% today, with a bearish technical signal despite oversold RSI readings. The stock offers a high dividend yield near 15% and trades below book value (P/B 0.91). Recent quarters show consistent EPS beats, with Q3 2026 results pending. The company's portfolio expansion to $107 billion in 2026 supports earnings growth, though cash flow trends show heavy reliance on financing activities.
The outlook balances high income potential against interest rate sensitivity. Analyst consensus is bullish with a $22 price target, but rising debt-to-asset ratios and mortgage rate volatility pose risks. Sustainable dividend coverage remains key for total return prospects amid market uncertainty.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
